Company intelligence / Profile preview

Retrotope

Los Altos, California, United Statesretrotope.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Retrotope developed a proprietary class of isotopically stabilized PUFAs to prevent lipid peroxidation-driven cellular degeneration. Lead candidate RT001 showed positive data in compassionate use studies but failed to meet endpoints in late-stage trials by early 2022. The company entered Chapter 11 bankruptcy and its assets were acquired by another entity.[7]

Therapeutic areas: OphthalmologyNeurology
Modalities: Small moleculesIsotopically stabilized polyunsaturated fatty acids (PUFAs)
Industry: Biotech

Drug pipeline

2 assets

RT001

Phase 3

Indications: Infantile Neuroaxonal Dystrophy, Friedreich's Ataxia, Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Retrotope.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Retrotope.